Strides Arcolab receives ANDA approval from US FDA

By: |
May 15, 2015 5:23 PM

Product to be launched immediately Strides Arcolab has received approval from the United States Food & Drug Administration (USFDA) for Lamivudine and Zidovudine tablets USP, 150 mg/300 mg. According to IMS data, the US market for Lamivudine and Zidovudine Tablets is approximately $120 million. The product will be manufactured at the company’s oral dosage facility […]

Product to be launched immediately

Strides Arcolab has received approval from the United States Food & Drug Administration (USFDA) for Lamivudine and Zidovudine tablets USP, 150 mg/300 mg.

According to IMS data, the US market for Lamivudine and Zidovudine Tablets is approximately $120 million. The product will be manufactured at the company’s oral dosage facility at Bangalore and marketed by Strides in the US Market. The product will be launched in the markets immediately.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.